Browse the evidence

The model demonstrated good predictive power as indicated by the AUC values at different time points.

The nomogram can be reliably used in clinical settings for risk assessment.

There are predisposing risk factors for type 2 diabetes that can be reviewed.

Understanding risk factors can help in tailoring prevention strategies.

Overall low-carbohydrate diet (LCD) scores were not associated with mortality in the whole population of the study.

Practitioners should note that overall LCD scores do not predict mortality risk in this population.

There are predisposing risk factors for type 2 diabetes that can be reviewed.

Understanding risk factors can help in tailoring prevention strategies for individuals.

Further studies, including clinical trials, are needed to investigate the effects of a low carbohydrate diet on type 2 diabetes.

There is a need for more rigorous research to clarify the impact of low carbohydrate diets on diabetes management.

By 2025, GLP-1RAs are anticipated to receive FDA approval for new indications including chronic kidney disease and heart failure.

Healthcare providers should stay informed about upcoming indications for GLP-1RAs to optimize treatment options.

White meat, red meat, dairy, starch, fruits, vegetables, and legumes intake were not associated with incident IBD.

Practitioners can consider that traditional food groups may not contribute to IBD risk as ultra-processed foods do.

Current evidence on the cardiovascular safety of tirzepatide is limited but suggestive.

Caution is advised when considering tirzepatide for patients with cardiovascular issues due to limited evidence.

Gastrointestinal adverse effects are the most common safety concern associated with incretin analogs.

Clinicians should monitor for gastrointestinal side effects when prescribing incretin analogs.

Weight loss may increase the risk for atherosclerosis among participants who were obese at baseline.

Weight loss in obese individuals should be approached with caution regarding atherosclerosis risk.

16.4% of participants were at high-risk for atherosclerosis as measured by cIMT.

A significant portion of the population studied is at high risk for atherosclerosis, indicating a need for preventive measures.

Aspiration therapy meets safety and effectiveness thresholds for incorporation into routine practice, but overall acceptance has been lower than other FDA-approved EBMTs.

Practitioners should be aware of the safety of aspiration therapy, but also its limited acceptance among patients.

The use of safe and effective weight-loss medications may influence referral patterns for MBS in the future.

Practitioners should consider the evolving landscape of obesity treatment when referring patients for MBS.

Null findings for mortality in trials should be interpreted cautiously due to a lack of statistical power.

Caution should be exercised when drawing conclusions from trials that did not primarily focus on mortality outcomes.

Conversional surgeries (e.g., RYGB, SADI-S, DS) are effective for managing post-bariatric recurrent weight gain (RWG) and diabetes recurrence, but carry higher risks of complications compared to primary surgery.

If you are gaining weight back after bariatric surgery and other treatments have failed, ask your doctor about conversional surgeries. These are more complex procedures that can effectively manage weight and diabetes, but they carry higher risks of complications. It is crucial to go to specialized centers with experienced surgeons and undergo strict postoperative surveillance.

POPs act as mitochondrial toxins at low doses, causing mitochondrial dysfunction which is a more plausible mechanism for T2D development than endocrine disruption alone.

POPs may damage your mitochondria, the energy powerhouses of your cells, contributing to diabetes. You can counteract this by improving mitochondrial function through exercise, calorie restriction, and eating plant-based foods rich in phytochemicals.

Decreased CPT1b expression in white adipose tissue does not quantitatively decrease whole-body energy expenditure enough to contribute to an obese phenotype.

Focusing on increasing fat tissue metabolism via CPT1b is likely ineffective for weight loss because fat tissue naturally has very low CPT1 activity compared to muscle and liver. Weight management strategies should prioritize interventions affecting metabolically active tissues or overall energy balance rather than targeting fat-specific fatty acid oxidation enzymes.

In the Greek adult population, the combined prevalence of overweight and obesity is approximately 47.5%, with significant gender and age-related variations where males exhibit higher overweight prevalence and obesity rates increase with age.

This survey indicates that nearly half of Greek adults are overweight or obese, with men carrying more excess weight and risk increasing as you age. This isn't just an individual issue but a population-wide trend driven by diet and activity levels. Focus on sustainable dietary changes and regular physical activity, as these are modifiable factors, regardless of how common they are in your social circle.

Activation of human brown adipose tissue (BAT) via cold exposure or pharmacological agents does not result in meaningful body weight loss and is not a viable strategy for obesity treatment.

Do not rely on cold exposure or brown fat supplements for weight loss. The energy burned by human brown fat is negligible compared to daily intake and is often offset by increased hunger. Focus on sustainable dietary changes and physical activity instead.

In overweight or obese adults with type 2 diabetes, patterns of weight regain or weight cycling following intentional weight loss do not significantly increase the risk of incident fractures or significantly reduce bone mineral density compared to sustained weight loss/maintenance.

If you have type 2 diabetes and are overweight, you do not need to fear that regaining some weight after a successful loss will increase your risk of breaking a bone. Studies show that the fracture risk for people who regain or cycle weight is similar to those who maintain their weight loss. Focus on maintaining overall health rather than stressing over minor weight fluctuations.

In Type 2 Diabetes, Myocardial Infarction, Hypertension, and Sleep Apnea, elevated C-reactive protein (CRP) is primarily driven by adiposity rather than independent inflammatory pathology, as the association attenuates or reverses upon adjustment for BMI.

If you have high blood pressure, diabetes, or a history of heart issues, your high CRP (inflammation) is likely caused by your weight, not a separate inflammatory disease. Focus on weight loss through diet and lifestyle changes rather than seeking anti-inflammatory medications, as reducing adiposity directly reduces the inflammation.

SGLT2 inhibitors improve cardiac energy efficiency in failing diabetic hearts by shifting fuel utilization from fatty acids to ketone bodies, which act as a 'super-fuel' that generates ATP more efficiently.

SGLT2 inhibitors change how your heart gets energy. Instead of struggling to burn fat, your heart efficiently burns ketones produced by the drug, which provides more energy with less stress, helping a failing heart function better.

The obesity epidemic is primarily driven by changes in the caloric quantity and quality of the food supply, specifically the industrialization of cheap, highly processed foods with supernormal appetitive properties, rather than by specific macronutrients like protein, fat, or carbohydrates.

Focus on the overall food environment rather than isolating single nutrients. The rise in obesity is linked to the availability of cheap, highly processed, convenient foods that are engineered to be overconsumed. Reducing reliance on these foods and increasing home-prepared meals may help mitigate intake.

SGLT2 inhibitors produce significantly less weight loss than predicted by urinary glucose excretion because of compensatory hyperphagia (increased energy intake).

If you are taking an SGLT2 inhibitor (like Jardiance or Farxiga), expect about 2-3 kg of weight loss, not the 7 kg you might calculate based on urine sugar loss. Your body will likely increase your hunger to compensate for the calories lost in urine. To maximize weight loss, you must actively manage your appetite and food intake, as the drug alone will not overcome this biological compensation.